| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | Id |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1235.232/expansion |
| Url | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232 |
| Version | 20230118 |
| Status | active |
| Date | 2023-01-18T01:03:05-05:00 |
| Name | InfluenzaVaccine_HD_CN_Grouping |
| Title | Influenza Vaccine_HD_CN_Grouping |
| Experimental | False |
| Realm | us |
| Authority | hl7 |
| Description | b.well created value set by Sr. Clinical Business Analyst for the Influenza Vaccine - Adult Care Need. |
| Purpose | (Clinical Focus: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.) |
No resources found
FHIR
{
"resourceType" : "ValueSet",
"id" : "2.16.840.1.113762.1.4.1235.232",
"meta" : {
"versionId" : "6",
"lastUpdated" : "2023-12-21T17:43:03.000-05:00",
"profile" : [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail" : {
"name" : "B.well Connected Health Author"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate" : "2024-06-04"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate" : "2023-01-18"
}
],
"url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232",
"identifier" : [
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113762.1.4.1235.232"
}
],
"version" : "20230118",
"name" : "InfluenzaVaccine_HD_CN_Grouping",
"title" : "Influenza Vaccine_HD_CN_Grouping",
"status" : "active",
"date" : "2023-01-18T01:03:05-05:00",
"publisher" : "B.well Connected Health Steward",
"description" : "b.well created value set by Sr. Clinical Business Analyst for the Influenza Vaccine - Adult Care Need.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "US"
}
]
}
],
"purpose" : "(Clinical Focus: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the Clinical Care Need for Influenza Vaccine - Adult and utilization in patients/users connected health.)",
"compose" : {
"include" : [
{
"valueSet" : [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.228"
]
},
{
"valueSet" : [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.229"
]
},
{
"valueSet" : [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.230"
]
},
{
"valueSet" : [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.231"
]
}
]
},
"expansion" : {
"identifier" : "urn:uuid:0a59887d-b142-4524-9cb0-4c257d3495f3",
"timestamp" : "2025-05-11T06:30:00-04:00",
"total" : 79,
"contains" : [
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "111",
"display" : "Influenza, live, trivalent, intranasal"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "120",
"display" : "diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "127787002",
"display" : "Administration of vaccine product containing only Haemophilus influenzae type b antigen (procedure)"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "135",
"display" : "Influenza, high-dose, split virus, trivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "140",
"display" : "Influenza, split virus, trivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "141",
"display" : "Influenza, split virus, trivalent, injectable, contains preservative"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "144",
"display" : "seasonal influenza, intradermal, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "146",
"display" : "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine."
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "148",
"display" : "Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "149",
"display" : "Influenza, live, quadrivalent, intranasal"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "150",
"display" : "Influenza, split virus, quadrivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "153",
"display" : "Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "155",
"display" : "Influenza, recombinant, trivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "158",
"display" : "Influenza, split virus, quadrivalent, injectable, contains preservative"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "161",
"display" : "Influenza, injectable,quadrivalent, preservative free, pediatric"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "16292241000119109",
"display" : "Administration of booster dose of vaccine product containing only Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to Clostridium tetani toxoid protein (procedure)"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "166",
"display" : "influenza, intradermal, quadrivalent, preservative free, injectable"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "168",
"display" : "Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "17",
"display" : "Haemophilus influenzae type b vaccine, conjugate unspecified formulation"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "170343007",
"display" : "Administration of first dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "170344001",
"display" : "Administration of second dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "170345000",
"display" : "Administration of third dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "170346004",
"display" : "Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure)"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "171",
"display" : "Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "185",
"display" : "Influenza, recombinant, quadrivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "186",
"display" : "Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "197",
"display" : "Influenza, high-dose, split virus, quadrivalent, injectable, preservative free"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "205",
"display" : "Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "310306005",
"display" : "Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "310307001",
"display" : "Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "310308006",
"display" : "Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "312869001",
"display" : "Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "312870000",
"display" : "Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "414001002",
"display" : "Administration of vaccine product containing only five component acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and inactivated whole Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "414259000",
"display" : "Administration of first dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type b and inactivated whole Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "415507003",
"display" : "Administration of second dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type b and inactivated whole Human poliovirus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "415712004",
"display" : "Administration of third dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type b and inactivated whole Human poliovirus antigens (procedure)"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "46",
"display" : "Haemophilus influenzae type b vaccine, PRP-D conjugate"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "47",
"display" : "Haemophilus influenzae type b vaccine, HbOC conjugate"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "48",
"display" : "Haemophilus influenzae type b vaccine, PRP-T conjugate"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "49",
"display" : "Haemophilus influenzae type b vaccine, PRP-OMP conjugate"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "50",
"display" : "DTaP-Haemophilus influenzae type b conjugate vaccine"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "51",
"display" : "Haemophilus influenzae type b conjugate and Hepatitis B vaccine"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "770608009",
"display" : "Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "770616000",
"display" : "Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "770617009",
"display" : "Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "770618004",
"display" : "Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "786846001",
"display" : "Administration of vaccine product containing only Haemophilus influenzae type b and Hepatitis B virus antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "786847005",
"display" : "Administration of vaccine product containing only Influenza A virus subtype H5N1 antigen (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "787016008",
"display" : "Administration of vaccine product containing only Influenza virus antigen in nasal dose form (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "787436003",
"display" : "Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b antigens (procedure)"
},
{
"system" : "http://snomed.info/sct",
"version" : "http://snomed.info/sct/731000124108/version/20250301",
"code" : "86198006",
"display" : "Administration of vaccine product containing only Influenza virus antigen (procedure)"
},
{
"system" : "http://hl7.org/fhir/sid/cvx",
"version" : "20250318",
"code" : "88",
"display" : "influenza virus vaccine, unspecified formulation"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90644",
"display" : "Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90647",
"display" : "Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90648",
"display" : "Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90653",
"display" : "Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90655",
"display" : "Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90656",
"display" : "Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90657",
"display" : "Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90658",
"display" : "Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90660",
"display" : "Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90661",
"display" : "Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90662",
"display" : "Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90672",
"display" : "Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90673",
"display" : "Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90674",
"display" : "Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90682",
"display" : "Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90685",
"display" : "Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90686",
"display" : "Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90687",
"display" : "Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90688",
"display" : "Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90689",
"display" : "Influenza virus vaccine, quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90694",
"display" : "Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90697",
"display" : "Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90698",
"display" : "Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90748",
"display" : "Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use"
},
{
"system" : "http://www.ama-assn.org/go/cpt",
"version" : "2025",
"code" : "90756",
"display" : "Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use"
},
{
"system" : "http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets",
"version" : "2025",
"code" : "G0008",
"display" : "Administration of influenza virus vaccine"
}
]
},
"text" : {
}
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.